GT Biopharma, Inc. Announces it has Completed Enrollment in Proof-of-concept Clinical Trial for its Novel Treatment for Motion Sickness April 10, 2018
GT Biopharma Inc. Announces >50% Enrollment in Proof-Of-Concept Clinical Trial For Its Novel Treatment For Motion Sickness March 29, 2018
GT Biopharma, Inc. Announces Additional Positive Data From Its Phase 1 Clinical Trial For Myasthenia Gravis and Potential for Acceleration of the Start of Its Phase 2 Trial March 26, 2018
GT Biopharma (GTBP: OTCQB) Announces Appointment of Shawn M Cross as Chairman and Chief Executive Officer February 15, 2018
GT Biopharma Announces Dr. Jeffrey Miller, Renowned NK Cell Cancer Specialist, Will Present at Cell Therapy Symposia February 13, 2018
GT Biopharma Announces Completion of Dosing in Phase 1 Clinical Trial of GTP-004 for Myasthenia Gravis January 9, 2018